Home > Haematology > EHA 2020 > Plasma Cell Dyscrasias > Daratumumab for light-chain amyloidosis

Daratumumab for light-chain amyloidosis

Presented By
Dr Efstathios Kastritis, National and Kapodistrian University of Athens, Greece
Conference
EHA 2020
Trial
Phase 3, ANDROMEDA
The ANDROMEDA study demonstrated clear clinical benefit when adding subcutaneous (SC) daratumumab to a combination with cyclophosphamide, bortezomib and dexamethasone (CyBorD) for patients with newly diagnosed light-chain (AL) amyloidosis. Chemotherapy-based combinations are commonly used in AL amyloidosis, but more effective treatments are needed. Dr Efstathios Kastritis (National and Kapodistrian University of Athens, Greece) presented the phase 3 ANDROMEDA study, which evaluated subcutaneous (SC) daratumumab in combination with cyclophosphamide, bortezomib, and dexamethasone (D-CyBorD) compared with CyBorD alone in newly diagnosed patients with AL amyloidosis [1]. In total, 388 patients with newly diagnosed AL amyloidosis were randomised to receive treatment with either CyBorD alone (n=193) or with the addition of SC daratumumab (n=195; 1,800 mg Q4W). The...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on